BeOne Medicines Ltd.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Form 10‑K to be signed on its behalf by the undersigned, thereunto duly authorized.
| BEONE MEDICINES LTD. | ||
| Date: February 26, 2026 | By: | /s/ JOHN V. OYLER |
|---|---|---|
| John V. Oyler | ||
| Chief Executive Officer and Chairman | ||
| (Principal Executive Officer) | ||
POWER OF ATTORNEY
Each person whose individual signature appears below hereby authorizes and appoints John V. Oyler, Aaron Rosenberg and Chan Lee, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney‑in‑fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10‑K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys‑in‑fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys‑in‑fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10‑K has been signed by the following persons in the capacities indicated below and on the dates indicated:
| Signature | Title | Date | |
|---|---|---|---|
| /s/ JOHN V. OYLER | Chief Executive Officer and Chairman | February 26, 2026 | |
| John V. Oyler | (Principal Executive Officer) | ||
| /s/ AARON ROSENBERG | Chief Financial Officer | February 26, 2026 | |
| Aaron Rosenberg | (Principal Financial Officer) | ||
| /s/ TITUS BALL | Chief Accounting Officer | February 26, 2026 | |
| Titus Ball | (Principal Accounting Officer) | ||
| /s/ OLIVIER BRANDICOURT | Director | February 26, 2026 | |
| Olivier Brandicourt | |||
| /s/ MARGARET DUGAN | Director | February 26, 2026 | |
| Margaret Dugan | |||
| /s/ MICHAEL GOLLER | Director | February 26, 2026 | |
| Michael Goller | |||
| /s/ ANTHONY C. HOOPER | Director | February 26, 2026 | |
| Anthony C. Hooper | |||
| /s/ RANJEEV KRISHANA | Director | February 26, 2026 | |
| Ranjeev Krishana | |||
| /s/ ALESSANDRO RIVA | Director | February 26, 2026 | |
| Alessandro Riva | |||
| /s/ CORAZON (CORSEE) D. SANDERS | Director | February 26, 2026 | |
| Corazon (Corsee) D. Sanders | |||
| /s/ SHALINI SHARP | Director | February 26, 2026 | |
| Shalini Sharp | |||
| /s/ XIAODONG WANG | Director | February 26, 2026 | |
| Xiaodong Wang | |||
| /s/ QINGQING YI | Director | February 26, 2026 | |
| Qingqing Yi | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.